A study published Wednesday suggests a surprising side effect of GLP-1 drugs such as Ozempic: they can be effective at ...
EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...
EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...
In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...
Healthy Returns: Weight loss drug race heats up with pill data from Viking Therapeutics, AstraZeneca
Wall Street is betting that the new wave of growth in the obesity space will be driven by pills that could offer more ...
Novo Nordisk reported earnings, posting some chunky year-over-year growth and far outperforming its only real rival at the ...
AstraZeneca PLC shed GBP15 billion of market capitalization on Tuesday, after investors were underwhelmed by early data from a trial of a weight-loss pill. The company (UK:AZN) said its lead product ...
I’d been wanting to lose weight for a while and the traditional methods just weren’t working for me. Deprive myself of carbs for a week and I would drop a measly 2lb. Hire a personal trainer – the ...
We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...
Novo Nordisk reports earnings Wednesday morning, with sales of blockbuster weight-loss drugs Ozempic and Wegovy expected to continue driving the Danish drugmaker's results higher.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback